Oncimmune announces the signature of Agreements with Roche and Cedars-Sinai to profile patients using Oncimmune's novel Infectious Disease panel

Oncimmune Holdings plc, the leading global immunodiagnostics group, today announces that it has signed two separate agreements with Roche Pharmaceuticals (“Roche”) and Cedars-Sinai Medical Center (“Cedars-Sinai”), in each case to use the Company’s newly developed and proprietary Infectious Disease panel.